News Releases
Apr 15 2021
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
Mar 17 2021
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Mar 10 2021
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
Mar 8 2021
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
Mar 8 2021
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
Mar 3 2021
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 1 2021
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
Feb 22 2021
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
Feb 3 2021
Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
Dec 14 2020
Avid Bioservices Announces Closing of Public Offering of Common Stock